Please participate in a survey to document patient experiences and needs for a submission to two Canadian agencies assessing Zanubrutinib.
Please use the link below to complete the survey, regardless of where you live.
Our goal is to ensure that the views of patients are reflected in the recommendations made by these two agencies to Provincial and Territorial Health Ministers regarding the provision of Zanubrutinib to CLL patients.
Please complete this survey if you have CLL and have received Zanubrutinib.
You do not need to live in Canada to complete this survey.
Click here to participate in the survey: surveymonkey.com/r/HD7MMJJ
The survey and the submission are a joint initiative of Lymphoma Canada and CLL Canada. The two agencies reviewing Zanubrutinib are Canadian Agency for Drugs and Technologies in Health review (cadth.ca) and the Institut national d'excellence en santé et en services sociaux in Quebec (inesss.qc.ca)